It looks like analysts revised down because script growth is not growing at a rate fast enough to cover expenses. There are you happy? I will be pumping all downgrades from analysts when the time comes.
The analysts now have so much cushion in their targets. Thus, the revisions and Price Targets will BE UP! No other choice.
Some do not even take the EU into account at all in their discounted present value analysis. That is tick tock tick tock. TROWE, FMR, INGALLS are ahead of the curve.
ANALYSTS will be revising their targets UP as AVNR BEATS the now current estimates by leaps and bounds. FY Q4 will be the deal breaker. (-0.10)? Followed up with FY Q1.
The current quarter OPEX is at most $21.9 M based on revised guidance in the Q3 call. Pill counts, script growth combined likely at 11% growth in July alone.
Run the numbers. IMHO, it will not be close and Net Earnings will be (-0,07) or so at most which is a Huge (0.03) BEAT. Thus, all 2013 estimates and price targets will be revised UPWARDS. The earnings revisions and new Price Targets will be UP not down.